Literature DB >> 11113870

Epidermal growth factor up-regulates CD44-dependent astrocytoma invasion in vitro.

M Monaghan1, K A Mulligan, H Gillespie, A Trimble, P Winter, P G Johnston, D McCormick.   

Abstract

CD44/hyaluronan interactions and epidermal growth factor (EGF) stimulation are both known to enhance tumour invasion in vitro. The frequent amplification of the EGF receptor (EGFR) in high-grade astrocytomas led to the examination of the hypothesis that CD44-dependent astrocytoma invasion is regulated by EGF. It has been shown that human astrocytoma cells express only the standard (haemopoietic) form of CD44 (CD44s) and that EGF up-regulates CD44 mRNA and protein in a time- and dose-dependent (10-100 ng/ml) manner. EGF stimulation did not result in induction of additional splice variants. No EGF-induced increase in CD44s was observed after treatment of cells with the wild-type EGFR tyrosine kinase inhibitor Tyrphostin AG1478 (30 nM). Up-regulation of CD44 by EGF is also prevented by the transcriptional inhibitor actinomycin D (5 microg/ml) and by blocking the MAP kinase (MAPK) pathway using the MEK inibitor U0126 (100 microM). CD44 up-regulation was associated with a 50% increase in invasion through hyaluronan-supplemented Matrigel(trade mark), which was abrogated by ligating CD44 with the specific antibody KM201. These results suggest that increased CD44 expression in response to EGF stimulation plays a significant role in astrocytoma invasion. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113870     DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH784>3.0.CO;2-M

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  8 in total

1.  Epidermal growth factor-regulated activation of Rac GTPase enhances CD44 cleavage by metalloproteinase disintegrin ADAM10.

Authors:  Toshiyuki Murai; Takayuki Miyauchi; Toshio Yanagida; Yasushi Sako
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

2.  Transforming growth factor β1 (TGFβ1) regulates CD44V6 expression and activity through extracellular signal-regulated kinase (ERK)-induced EGR1 in pulmonary fibrogenic fibroblasts.

Authors:  Shibnath Ghatak; Roger R Markwald; Vincent C Hascall; William Dowling; Robyn Grayson Lottes; John E Baatz; Gyada Beeson; Craig C Beeson; Mark A Perrella; Victor J Thannickal; Suniti Misra
Journal:  J Biol Chem       Date:  2017-04-07       Impact factor: 5.157

3.  Induction of membrane-type-1 matrix metalloproteinase by epidermal growth factor-mediated signaling in gliomas.

Authors:  Timothy E Van Meter; William C Broaddus; Harcharan K Rooprai; Geoffrey J Pilkington; Helen L Fillmore
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

Review 4.  CD44: molecular interactions, signaling and functions in the nervous system.

Authors:  Joanna Dzwonek; Grzegorz M Wilczynski
Journal:  Front Cell Neurosci       Date:  2015-05-07       Impact factor: 5.505

5.  Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival.

Authors:  Yuan Pan; Laura J Smithson; Yu Ma; Dolores Hambardzumyan; David H Gutmann
Journal:  Oncotarget       Date:  2017-05-16

Review 6.  Engineering Three-Dimensional Tumor Models to Study Glioma Cancer Stem Cells and Tumor Microenvironment.

Authors:  Henry Ruiz-Garcia; Keila Alvarado-Estrada; Paula Schiapparelli; Alfredo Quinones-Hinojosa; Daniel M Trifiletti
Journal:  Front Cell Neurosci       Date:  2020-10-16       Impact factor: 5.505

Review 7.  Mechanisms of Invasion in Glioblastoma: Extracellular Matrix, Ca2+ Signaling, and Glutamate.

Authors:  Jae-Seon So; Hyeono Kim; Kyung-Seok Han
Journal:  Front Cell Neurosci       Date:  2021-06-02       Impact factor: 5.505

8.  WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition.

Authors:  Chandra Prakash Prasad; Shivendra Kumar Chaurasiya; William Guilmain; Tommy Andersson
Journal:  J Exp Clin Cancer Res       Date:  2016-09-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.